Vidarbha News

Oral Mucositis Therapeutics Market Expected to Increase with CAGR of 6.6% Throughout the Study Period (2018-30) in the 7MM, According to DelveInsight

 Breaking News
  • No posts were found

Oral Mucositis Therapeutics Market Expected to Increase with CAGR of 6.6% Throughout the Study Period (2018-30) in the 7MM, According to DelveInsight

August 13
13:01 2021
Oral Mucositis Therapeutics Market Expected to Increase with CAGR of 6.6% Throughout the Study Period (2018-30) in the 7MM, According to DelveInsight
Oral Mucositis Market
The rising incidence of cancer cases, the expected approval, and widespread adoption of emerging therapies such as Avasopasem, BupiZenge, and others are expected to drive growth in the Oral Mucositis market size.

DelveInsight’s Oral Mucositis market report provides an in-depth understanding of the Oral Mucositis, historical and forecasted epidemiology, as well as Oral Mucositis market trends in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan). The Oral Mucositis market report also covers current treatment practices, emerging drugs, Oral Mucositis market share of individual therapies, as well as current and forecasted Oral Mucositis market size from 2018 to 2030, segmented by seven major markets.

Some of the Important Findings from the Oral Mucositis Market Report

  • According to Sonis et al., Oral Mucositis prevalence in the general cancer patient population ranges from 30% to 40%.

  • As per DelveInsight’s Oral Mucositis epidemiology insights, the total incident cases were found to be 1,480,453 in the 7MM in 2020.

  • According to DelveInsight, the highest number of Oral Mucositis incident cases among the grade-specific was of Grade III, followed by Grade I, II and IV respectively in the United States in 2020.

  • Key players such as Galera Therapeutics, Monopar Therapeutics, Soligenix, NeoMedLight, BrainCool, MuReva (Lumitex),  Oncozenge, and others are involved in developing drugs/devices for Oral Mucositis. 

  • Galera’s lead product candidate Avasopasem, also known as Avasopasem manganese or GC4419, is a highly selective small molecule superoxide dismutase (SOD) mimetic under investigation for the treatment of radiation-induced severe oral mucositis.

  • SGX942 (Dusquetide) is an investigational agent being developed by Soligenix. SGX942 is a rapid 4-minute infusion given twice a week during chemotherapy and/or radiation treatment to reduce the duration and severity of severe oral mucositis.

  • MuReva is developing the MuReva Phototherapy System, which is an intraoral illuminated mouthpiece that can deliver light to all soft tissue susceptible to oral mucositis at the same time.

To get a  detailed analysis of the WHO oral mucositis grading scale, request sample @ Oral Mucositis Guidelines

The Oral Mucositis market report also discusses current Oral Mucositis treatment practices/algorithms, Oral Mucositis market drivers, Oral Mucositis market barriers, and unmet medical needs in order to curate the best opportunities and assess the market’s underlying potential.

Oral Mucositis: Overview

Oral Mucositis is characterized by erythematous and ulcerative lesions of the oral mucosa in cancer patients receiving chemotherapy and/or radiation therapy to fields involving the oral cavity. This can cause a variety of issues, including pain, nutritional issues due to inability to eat, and an increased risk of infection due to open sores in the mucosa.

Oral Mucositis Epidemiology Segmentation

The Oral Mucositis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Oral Mucositis Total Incident Cases 

  • Oral Mucositis Grade-Specific Incident Cases 

  • Oral Mucositis Total Treated Cases 

Oral Mucositis Treatment Landscape

The current clinical management of Oral Mucositis focuses primarily on palliative measures such as pain management, nutritional support, and the maintenance of good oral hygiene. Some of the FDA-approved drugs/devices used for Oral Mucositis treatment include Kepivance (palifermin), Episil, MuGard, and Chemo Mouthpiece.

Oral Mucositis Market 

The Oral Mucositis market size in the 7MM might grow at a CAGR of 6.6%.

The rising incidence of cancer cases, the expected approval and widespread adoption of emerging therapies such as Avasopasem, SGX942, BupiZenge, and others and an increase in R&D activities are expected to drive growth in the Oral Mucositis market size. 

Oral Mucositis Emerging Therapies/Devices and Key Companies 

  • Avasopasem (GC4419): Galera Therapeutics

  • SGX942: Soligenix

  • Validive (Clonidine Lauriad): Monopar Therapeutics

  • CareMin650: NeoMedLight

  • Cooral/CoolPrevent: BrainCool

  • MuReva Phototherapy System: MuReva (Lumitex)

  • BupiZenge: Oncozenge 

For complete information on the emerging therapies, visit @ Oral Mucositis Treatment Drugs

Oral Mucositis Market Driver

  • Increasing Incidence of Cancer patients

  • Ongoing Research and Development

  • Robust Oral Mucositis Pipeline Activity

Oral Mucositis Market Barriers

  • Limited or No Awareness About the Disease

  • Lack of Diagnostic Methods

  • The High Cost of Treatment

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Oral Mucositis Key Companies: Galera Therapeutics, Monopar Therapeutics, Soligenix, NeoMedLight, BrainCool, MuReva (Lumitex),  Oncozenge, among others. 

Oral Mucositis Key Pipeline Therapies/Devices: Avasopasem(GC4419), SGX942 , Validive (Clonidine Lauriad), CareMin650, Cooral/CoolPrevent, MuReva Phototherapy System, BupiZenge,and others.

Oral Mucositis Segmentation: By Geography, By Oral Mucositis therapies

Analysis: Comparative and conjoint analysis of Oral Mucositis emerging therapies/devices

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

1.

Key Insights

2.

Executive Summary of Oral Mucositis

3.

SWOT Analysis of Oral Mucositis

4.

Oral Mucositis: Market Share (%) Distribution Overview at a Glance: By Country

5.

Oral Mucositis Epidemiology and Market Methodology

6.

Oral Mucositis: Disease Background and Overview

7.

Diagnosis of Oral Mucositis

8.

Oral Mucositis Epidemiology and Patient Population

9.

Oral Mucositis Epidemiology Scenario: 7MM

10.

Oral Mucositis The United States Epidemiology

11.

Oral Mucositis EU-5 Epidemiology

12.

Oral Mucositis Japan Epidemiology

13.

Current Treatment Practices: Oral Mucositis

14.

Prevention of Oral Mucositis

15.

Guidelines of Oral Mucositis

16.

Oral Mucositis Unmet Needs

17.

Patient Journey of Oral Mucositis

18.

Key Endpoints in Oral Mucositis Clinical Trials

19.

Oral Mucositis Marketed Therapies

20.

Oral Mucositis Emerging Therapies

21.

Oral Mucositis: Seven Major Market Analysis

22.

Oral Mucositis 7MM Market Size

23.

Oral Mucositis The United States Market Size

24.

Oral Mucositis EU-5 Market Size

25.

Oral Mucositis Japan Market Size

26.

Market Access and Reimbursement of Oral Mucositis Therapies

27.

Market Drivers of Oral Mucositis

28.

Market Barriers of Oral Mucositis

29.

Appendix

30.

DelveInsight Capabilities

31.

Disclaimer

32.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Stomatitis Pipeline Insights 

Get a comprehensive analysis of Stomatitis pipeline therapies and key companies such as Galera Therapeutics, Otsuka Pharmaceuticals, Enzychem Lifesciences Corporation, Izun Pharma Ltd, Soligenix, Santalis Pharmaceuticals, Inc., Astellas Pharma, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/